Clinico-Histomorphological and Mib-1 Analysis of Recurrent Meningiomas: A Retrospective Study

Abstract

Introduction

Meningiomas are the most common primary brain tumors in adults, comprising 37.6% of central nervous system neoplasms. Though gross total resection is the treatment of choice, meningiomas recur even after complete resection. Additionally, meningiomas with a high Ki67/MIB-1 labeling index (LI) have a higher recurrence rate.

Aim

This article analyzes the clinico-histomorphological features of recurrent meningiomas and compares the expression of MIB-1 LI of primary and recurrent tumors.

Materials and Methods

This was a retrospective observational study of 50 recurrent meningiomas diagnosed between 2019 and 2023. Tumors were analyzed for site, radiological/histopathological features, and expression of MIB-1 LI in both primary and recurrent tumors.

Results

Thirty-four percent of the recurrent cases were between 41 and 50 years of age, 58% of the recurrent cases were males. Recurrence was most commonly seen in the frontal region (26%; n = 13) and 52% cases recurred between 1 and 10 years after primary resection. Of the primary tumors, 30 cases (60%) were grade 1, 16 cases (32%) were grade 2, and 4 cases (8%) were grade 3. Mean MIB-1 of primary meningiomas was 4.25% overall and 1.8% for grade 1. Progression in grade was noted in 15 cases with 5 cases showing brain invasion on recurrence while 17/30 grade 1, 14/16 grade 2, and 4/4 grade 3 tumors recurred with no change in grade. Overall mean MIB-1 LI of recurrent tumors was 5.4%.

Conclusion

Although MIB-1 LI is not an independent criterion for tumor grading, it can be used as an additional tool to identify at-risk patients and recommend close follow-up.

Keywords

histomorphology - MIB-1 LI - Ki67 - meningioma - recurrence

Publication History

Article published online:
08 September 2025

• References

• 1 WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed.. Lyon: International Agency for Research on Cancer; 2021
• 2 Ostrom QT, Gittleman H, Fulop J. et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncol 2015; 17 (Suppl. 04) iv1-iv62
• 3 Wach J, Lampmann T, Güresir Á. et al. FORGE: a novel scoring system to predict the MIB-1 labeling index in intracranial meningiomas. Cancers (Basel) 2021; 13 (14) 3643
• 4 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 5 Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol 2018; 14 (21) 2161-2177
• 6 Menger R, Connor Jr DE, Chan AY, Jain G, Nanda A. Degree of resection and Ki-67 labeling index for recurring meningiomas. Cureus 2017; 9 (11) e1820
• 7 Roychowdhury M. Ki67. PathologyOutlines.com website. Accessed September 10, 2023 at: https://www.pathologyoutlines.com/topic/stainski67.html
• 8 Lampmann T, Wach J, Schmitz MT, Güresir Á, Vatter H, Güresir E. Predictive power of MIB-1 vs. mitotic count on progression-free survival in skull-base meningioma. Cancers (Basel) 2022; 14 (19) 4597
• 9 Nilkanthe R, Modi M, Trivedi P, Shah A, Shah J. Prospective study of meningioma & diagnostic validity of MIB-1 index in grading of meningioma. IP Arch Cytol Histopathol Res 2016; 1 (01) 14-20
• 10 Haddad AF, Young JS, Kanungo I. et al. WHO grade I meningioma recurrence: identifying high risk patients using histopathological features and the MIB-1 index. Front Oncol 2020; 10: 1522
• 11 Prat-Acín R, Guarín-Corredor MJ, Galeano-Senabre I, Ayuso-Sacido A, Vera-Sempere F. Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II. J Clin Neurosci 2021; 86: 32-37
• 12 Suh DH, Kim DS, Kim OL. The diagnostic significance of AgNORs and MIB-1 labelling index in atypical meningioma. J Pathol Transl Med 1998; 32 (11) 1008-1014
• 13 Nagahama A, Yashiro M, Kawashima T. et al. Combination of p53 and Ki67 as a promising predictor of postoperative recurrence of meningioma. Anticancer Res 2021; 41 (01) 203-210
• 14 Behling F, Fodi C, Wang S. et al. Mib1 expression is increased in meningiomas with histopathological evidence of Cns invasion. Preprints 2021; 2021080221
• 15 Liu N. Song Sy, Jiang Jb, Wang Tj, Yan Cx. The prognostic role of Ki-67/MIB-1 in meningioma: a systematic review with metaanalysis. Medicine (Baltimore) 2020; 99 (09) e1864
• 16 Weller RO. Microscopic morphology and histology of the human meninges. Morphologie 2005; 89 (284) 22-34
• 17 Ghannam JY, Al Kharazi KA. Neuroanatomy, Cranial Meninges. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; ; January 2024
• 18 Bordoni B, Simonelli M, Lagana MM. Tentorium cerebelli: muscles, ligaments, and dura mater, part 1. Cureus 2019; 11 (09) e5601
• 19 Joseph JT. Diagnostic Neuropathology Smears. Philadelphia, PA: Lippincott Williams & Wilkins; 2007
• 20 Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 154 (03) 223-235
• 21 Gerdes J, Li L, Schlueter C. et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138 (04) 867-873
• 22 Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23 (28) 7212-7220
• 23 Chung YR, Jang MH, Park SY, Gong G, Jung WH. Korean Breast Pathology Ki-67 Study Group. Interobserver variability of Ki-67 measurement in breast cancer. J Pathol Transl Med 2016; 50 (02) 129-137
• 24 de Carvalho GTC, da Silva-Martins WC, de Magalhães KCSF. et al. Recurrence/regrowth in grade I meningioma: how to predict?. Front Oncol 2020; 10: 1144
• 25 Li J, Liang R, Song C, Xiang Y, Liu Y. Prognostic value of Ki-67/MIB-1 expression in meningioma patients: a meta-analysis. Crit Rev Eukaryot Gene Expr 2019; 29 (02) 141-150
• 26 Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002; 94 (05) 1538-1547
• 27 Nguyen MP, Morshed RA, Dalle Ore CL. et al. Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma. J Neurosurg 2022; 138 (01) 86-94
• 28 Barrett OC, Hackney JR, McDonald AM, Willey CD, Bredel M, Fiveash JB. Pathologic predictors of local recurrence in atypical meningiomas following gross total resection. Int J Radiat Oncol Biol Phys 2019; 103 (02) 453-459
• 29 Hoffmann E, Clasen K, Frey B. et al. Retrospective analysis of recurrence patterns and clinical outcome of grade II meningiomas following postoperative radiotherapy. Radiat Oncol 2021; 16 (01) 116
• 30 Chen WC, Magill ST, Wu A. et al. Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J Neurosurg 2018; 130 (02) 443-450
• 31 Abry E, Thomassen IØ, Salvesen ØO, Torp SH. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Pract 2010; 206 (12) 810-815
• 32 Matias JG, Jusue-Torres I, Martin B. et al. Value of K _i -67 labeling index in predicting recurrence of WHO grade I cranial base meningiomas. J Neurol Surg B Skull Base 2019; 80 (03) 287-294
• 33 Tao Y, Liang G, Li Z. et al. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. Br J Neurosurg 2012; 26 (05) 700-704
• 34 Kent CL, Mowery YM, Babatunde O. et al. Long-term outcomes for patients with atypical or malignant meningiomas treated with or without radiation therapy: a 25-year retrospective analysis of a single-institution experience. Adv Radiat Oncol 2021; 7 (03) 100878
• 35 Lee SH, Lee EH, Sung KS, Kim DC, Kim YZ, Song YJ. Ki67 index is the most powerful factor for predicting the recurrence in atypical meningioma : retrospective analysis of 99 patients in two institutes. J Korean Neurosurg Soc 2022; 65 (04) 558-571
• 36 Choi Y, Lim DH, Yu JI. et al. Prognostic value of KI-67 labeling index and postoperative radiotherapy in WHO grade II meningioma. Am J Clin Oncol 2018; 41 (01) 18-23
• 37 Ozen O, Demirhan B, Altinörs N. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol 2005; 24 (05) 219-224
• 38 Hortobágyi T, Bencze J, Varkoly G, Kouhsari MC, Klekner Á. Meningioma recurrence. Open Med (Wars) 2016; 11 (01) 168-173
• 39 Gaillard F, Silverstone L, Walizai T. et al. Meningioma. Accessed August 27, 2025 at: https://doi.org/10.53347/rID-1659
• 40 Perry A, Brat DJ. Practical Surgical Neuropathology: A Diagnostic Approach, Normal Brain Histology. 2nd ed.. Philadelphia: Elsevier; 2018: 19-37
• 41 Uzüm N, Ataoğlu GA. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori 2008; 94 (03) 389-397
• 42 Terzi A, Saglam EA, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract 2008; 204 (05) 305-314
• 43 Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 2007; 27 (05) 407-412
• 44 Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med 1999; 123 (09) 793-800
• 45 Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 2004; 66 (1-2): 29-37
• 46 Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008; 79 (05) 574-580
• 47 Kalala JP, Caemaert J, De Ridder L. Primary resected meningiomas: relapses and proliferation markers. In Vivo 2004; 18 (04) 411-416
• 48 Kim YJ, Ketter R, Steudel WI, Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007; 128 (01) 118-125
• 49 Marciscano AE, Stemmer-Rachamimov AO, Niemierko A. et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg 2016; 124 (01) 106-114